

New Products - Veletri

Veletri (**epoprostenol (as sodium)**) (prostacyclin) has two major pharmacological actions: (1) direct vasodilatation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. Veletri is indicated for the long-term treatment, via continuous intravenous infusion, in WHO functional class III or IV patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. Veletri is contraindicated in patients with congestive heart failure arising from severe left ventricular dysfunction, because it was found to increase mortality in such patients. Veletri should not be used chronically in patients who develop pulmonary oedema during dose-ranging. Veletri powder for infusion (epoprostenol 500 mcg and 1.5 mg) is available as a single use vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.